Goldman Sachs
AGTC

Goldman Sachs’s Applied Genetic Technologies Corporation AGTC Stock Holding History

Goldman Sachs’s Portfolio AGTC Stock Details AGTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-90,969
Closed -$97K – 6883
2022
Q1 		$97K Buy
90,969
+3,044
+3% +$5.53K ﹤0.01% 6119
2021
Q4 		$167K Sell
87,925
-22,931
-21% -$54.9K ﹤0.01% 5965
2021
Q3 		$334K Buy
110,856
+42,069
+61% +$150K ﹤0.01% 5431
2021
Q2 		$269K Sell
68,787
-3,086
-4% -$12.8K ﹤0.01% 5579
2021
Q1 		$365K Buy
+71,873
New +$373K ﹤0.01% 5320
2020
Q4 		– Sell
-17,640
Closed -$86K – 5801
2020
Q3 		$86K Buy
+17,640
New +$96.3K ﹤0.01% 5114
2020
Q2 		– Sell
-42,786
Closed -$140K – 5572
2020
Q1 		$140K Buy
+42,786
New +$225K ﹤0.01% 4851
2018
Q3 		– Sell
-60,142
Closed -$223K – 5863
2018
Q2 		$223K Buy
+60,142
New +$278K ﹤0.01% 4950
2017
Q3 		– Sell
-143,606
Closed -$732K – 6941
2017
Q2 		$732K Buy
143,606
+131,439
+1,080% +$738K ﹤0.01% 4742
2017
Q1 		$84K Sell
12,167
-48,315
-80% -$377K ﹤0.01% 6134
2016
Q4 		$566K Sell
60,482
-2,268
-4% -$20.4K ﹤0.01% 4944
2016
Q3 		$614K Buy
62,750
+11,882
+23% +$160K ﹤0.01% 4845
2016
Q2 		$719K Buy
50,868
+14,357
+39% +$224K ﹤0.01% 4506
2016
Q1 		$510K Buy
+36,511
New +$536K ﹤0.01% 4720
2015
Q2 		– Sell
-23,146
Closed -$463K – 7500
2015
Q1 		$463K Sell
23,146
-45,624
-66% -$1.02M ﹤0.01% 5213
2014
Q4 		$1.45M Buy
+68,770
New +$1.4M ﹤0.01% 4182
2014
Q3 		– Sell
-12,714
Closed -$294K – 7316
2014
Q2 		$294K Buy
+12,714
New +$224K ﹤0.01% 5861

Other funds holding AGTC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CG
Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs's AGTC Position: Q2 2022 in Review

Goldman Sachs sold out of Applied Genetic Technologies Corporation (AGTC) in Q2 2022, closing a stake of 90,969 shares — an estimated $97K sold.

Goldman Sachs first reported a position in AGTC in Q2 2014 and held it in 17 quarters. The position peaked at $1.45M in Q4 2014. 47 funds tracked by Wall St. Rank hold AGTC as of Q2 2022.

  • Goldman Sachs reported no remaining Applied Genetic Technologies Corporation position as of Q2 2022 after selling out during the quarter.
  • Goldman Sachs sold 90,969 Applied Genetic Technologies Corporation shares in Q2 2022, an estimated $97K.
  • Goldman Sachs first reported a position in Applied Genetic Technologies Corporation in Q2 2014 and held it in 17 quarters.
  • Goldman Sachs's Applied Genetic Technologies Corporation position peaked at $1.45M in Q4 2014.
  • 47 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q2 2022.

Based on Goldman Sachs's 13F filing for Q2 2022, filed 15 Aug 2022.